A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
Recruiting now · Phase 3
Conditions studied: Respiratory Syncytial Virus (RSV)
In brief
The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adults with health condition(s) that can put them at an increased risk of severe RSV disease It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
Key facts
- Study ID
- NCT07543380
- Run by
- Pfizer
- People needed
- 130
- Starts
- 2026-05-11
- Expected to finish
- 2026-08-31
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tsuchiura Beryl Clinic — Tsuchiura, Ibaraki, Japan (enrolling)
- Nihonbashi Sakura Clinic — Chuo-ku, Tokyo, Japan (enrolling)
- Tokyo-Eki Center-building Clinic — Chuo-ku, Tokyo, Japan (enrolling)
- Fukuwa Clinic — Chuo-ku, Tokyo, Japan (enrolling)
- Tenjin Sogo Clinic — Fukuoka, Japan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.